share_log

Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $7

Benzinga Real-time News ·  Aug 5, 2022 09:20

Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $10 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment